Relationship Between Tumor Markers, ER/PR, HER2, Ki67 and CyclinA2 and Clinical Efficacy of Neoadjuvant Chemotherapy
Xiao Yu,Li Huiping,Lei Yutao,肖宇,李惠平,雷玉涛,赵红梅,修典荣,王晶,王墨培,张淑兰,张照辉,梁丽,马力文
DOI: https://doi.org/10.3969/j.issn.1009-6604.2011.02.021
2011-01-01
Abstract:Objective To explore the efficacy of neoadjuvant chemotherapy for breast cancer and predictive value of ER/PR,HER2,Ki67,and CyclinA2 in women with local advanced breast cancer(LABC). Methods From October 2004 to December 2009,50 patients with stage Ⅰ-Ⅲ primary breast cancer received 2-6 cycles of neoadjuvant chemotherapy with anthracycline(EC/FEC) or taxanes-based(TP/TC or TE/PE/TEC) in our hospital.Forty-five of them were followed by definitive surgery and adjuvant chemotherapy.Estrogen receptor(ER)/progesterone receptor(PR)(50 cases),HER2(48 cases),Ki67(26 cases) and CyclinA2(18 cases) were examined with immunohistochemistry before the neoadjuvant chemotherapy.Clinical responds,tumor lessen ratio,and toxicity of the treatment were estimated by ultrasonography and palpation afterwards.Results The medium maximum diameter of the tumors was 3.6 cm before neoadjuvant chemotherapy,and 2.2 cm after the treatment,no significant changes were observed(Z=-5.723,P=0.000).The clinical response rate was 76.0%(38/50) in the patients [6%(3/50) CR and 70%(35/50) PR],and SD was 22%(11/50),PD 2.0%(1/50).In the 45 patients who underwent surgery,pCR was found in 3 cases(3/45,6.7%),and tpCR in 3(3/45,6.7%).The 4-year disease-free survival(DFS) rate was 86.2%,and total survival rate was 93.1% [medium DFS 62.4 months,SE: 2.535,95%CI(57.450-67.388)].No significant difference was observed in tumor lessen ratio between pre-menopause and post-menopause patients(46.4% vs.40.6%,P=0.536),patients with positive and negative hormone receptors(43.0% vs.42.2%,P=0.929),patients with positive and negative HER2(41.3% vs.43.9%,P=0.774),Ki67(47.2% vs.43.1%,P=0.363),and CyclinA2(34.3% vs.50.0%,P=0.375),or among those with high,moderate or low differentiation(44.1%,42.9%,and 41.3%;P=0.983) or different chemotherapy regimen(TP/TC 52.7%,TE/PE/TEC 39.8%,and EC/FEC 38.9%,P=0.440). Conclusions Patients with stage Ⅰ-Ⅲ invasive breast cancers can benefit from taxanes/anthracycline-based neoadjuvant chemotherapy with well-tolerated toxic.No evidence showing any relationship between tumor lessen ratio and expression levels of ER/PR,HER2,Ki67 and CyclinA2.